
08/08/2025
Cystic fibrosis (CF) is a genetic condition that primarily affects the lungs and digestive system. Over the years, treatment has shifted toward addressing the underlying genetic causes rather than just managing symptoms.
Alyftrek, a triple-combination therapy approved by the FDA in 2024, is one of the latest additions to this approach. It is designed to improve CFTR protein function in people with specific gene mutations like F508del, potentially enhancing lung function and reducing mucus buildup. It also offers once-daily dosing and expanded mutation coverage compared to earlier therapies.
While Alyftrek is not suitable for everyone and comes with considerations such as liver health and drug interactions, it adds to the options available for personalized CF care.
Learn more about ongoing research focused on advancing treatment strategies and improving outcomes for people with CF:
https://myacare.com/blog/nextgen-cf-therapy-understanding-alyftrek